2.21
-0.06(-2.64%)
Currency In USD
| Previous Close | 2.27 |
| Open | 2.28 |
| Day High | 2.32 |
| Day Low | 2.17 |
| 52-Week High | 3.31 |
| 52-Week Low | 1.01 |
| Volume | 829,662 |
| Average Volume | 1.4M |
| Market Cap | 626.91M |
| PE | -5.67 |
| EPS | -0.39 |
| Moving Average 50 Days | 1.9 |
| Moving Average 200 Days | 1.6 |
| Change | -0.06 |
If you invested $1000 in Erasca, Inc. (ERAS) since IPO date, it would be worth $126.79 as of October 23, 2025 at a share price of $2.21. Whereas If you bought $1000 worth of Erasca, Inc. (ERAS) shares 3 years ago, it would be worth $301.5 as of October 23, 2025 at a share price of $2.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, t
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NE
Erasca to Present at Upcoming Investor Conferences in June
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, tod